Search results
FDA approves Abbott's dissolving stent for leg artery disease By Investing.com
Investing.com· 5 days agoThe U.S. Food and Drug Administration has approved Abbott's Esprit BTK Everolimus Eluting Resorbable...
Fading lights: Comprehensive study unveils multiple threats to North America's firefly populations
Phys.org· 5 days agoThe study, published in Science of the Total Environment, "Illuminating Patterns of Firefly...
The problems with the middle class and ketamine therapy
Market Watch· 1 day agoToday, Venessa comes on the show and explains why the inflation shock of recent years put the final...
Popular media site files Chapter 11 bankruptcy
TheStreet.com· 6 days agoWhen you hang your hat on denying the results of the 2020 election and supporting various other conspiracy theories, you place your business on tenuous legal grounds. Fox News famously supported ...
Early glance at renewed effort to reintroduce wolverines to Colorado presented at CPW Commission...
KOAA5· 2 days agoColorado wildlife officials have dusted off a drafted plan to reintroduce wolverines to the state, a...
Campus riots undermine the Palestinian cause, but Netanyahu’s allies undermine Israel’s
The Hill· 1 day agoAfter some days during which students — as well as outsiders who were not members of the university...
MELTDOWN: West Kootenay wildlife rely on a disappearing snowpack
Houston Today· 2 days agoIn case you missed them, read part one on drinking water, and part two on outdoor recreation. At...
EXPLAINER-What you need to know about the 2024 US presidential election
Reuters via Yahoo Finance· 3 days agoThe 2024 U.S. presidential election is making history on many levels. It pits a former president, Republican Donald Trump, against the current one, Democrat Joe Biden, in the country's first ...
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss...
KAMR Amarillo· 4 days agoDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
The Longview News-Journal· 1 day agoJohnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive ...